Haydeh Payami, Ph.D., a leading geneticist recruited to the UAB-Hudson Alpha Center for Genomic Medicine and UAB Personalized Medicine Institute, is exploring the protective power of coffee and nicotine — and the mysteries of the microbiome — in Parkinson’s disease.
The drug inhibits the activity of a kinase enzyme called LRRK2, and it showed no pathology in rat lungs, kidneys or livers.
A new report demonstrates that clinical and genetic factors affecting dose requirements for warfarin vary by race.
UAB researchers find a chemical pathway — a glutamate transporter — that may be causing seizures and shorten survival rates for patients with brain tumors.
UAB is one of five centers named to host the first class of fellows in the Edmond J. Safra Fellowship in Movement Disorders.
UAB has established the third multidisciplinary comprehensive clinic in the world for transverse myelitis, a rare spinal cord disease.
UAB has received prestigious designation as a Comprehensive Stroke Center from the Joint Commission and American Heart Association.
Research to identify a new approach to treat Alzheimer’s disease gets new funding after a pilot grant from the Alabama Drug Discovery Alliance.
Robin Lorenz, M.D., Ph.D. and Anthony Nicholas, M.D., Ph.D., were honored with the UAB President’s Award for Excellence in Teaching.
The UAB studies are designed to test the safety and tolerability of CBD oil in patients with intractable seizures. CBD oil, a derivative of the cannabis plant, is delivered orally as an oily liquid.